# Sources — Barbara Jordan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 4, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Texas State Historical Association. “Jordan, Barbara Charline,” *Handbook of Texas Online*. Supports her birth on February 21, 1936, in Houston, the youngest of three daughters, and her childhood in the Fifth Ward; Texas Southern University (1956) and Boston University law school (1959); election to the Texas Senate in 1966 as the first Black state senator since 1883; election to Congress in 1972 as the first Black woman from a Southern state; her 1974 Judiciary Committee speech and its quoted sentence; the 1976 convention keynote; her retirement from Congress in 1979 to become the Lyndon Baines Johnson Public Service Professor; “a form of multiple sclerosis” and a wheelchair in her later years; a near-drowning at her home in 1988; and her death in Austin on January 17, 1996, of pneumonia and leukemia, with burial in the State Cemetery. https://www.tshaonline.org/handbook/entries/jordan-barbara-charline
2. U.S. House of Representatives, History, Art & Archives. “JORDAN, Barbara Charline.” Supports that she declined a fourth term, downplaying reports about her poor health and citing her “internal compass”; the Lyndon Johnson chair at the LBJ School, where she taught until the early 1990s; convention speeches in 1988 and 1992, the 1992 keynote “amid a lengthy battle with multiple sclerosis”; and her death in Austin on January 17, 1996, from pneumonia that was a complication of leukemia. https://history.house.gov/People/Listing/J/JORDAN,-Barbara-Charline-(J000266)/
3. Boyer EJ (*Los Angeles Times*). “Barbara Jordan, voice of conscience, dead at 59,” *The Spokesman-Review*, January 18, 1996. Obituary: supports her career, the Presidential Medal of Freedom in 1994, that she had battled multiple sclerosis for several years and moved about in a wheelchair or with a walker, and, from the head of the LBJ School and a University of Texas official, that she died of pneumonia as a complication of leukemia. https://www.spokesman.com/stories/1996/jan/18/barbara-jordan-voice-of-conscience-dead-at-59-she
4. Voice of America Learning English. “Barbara Jordan, 1936-1996: A Powerful Voice for Justice and Social Change,” April 21, 2007. Supports the widespread reports, when she left Congress, that failing health was the cause; that it was later announced she had multiple sclerosis; and that she spoke from a wheelchair at the 1988 convention. https://learningenglish.voanews.com/amp/a-23-2007-04-21-voa2-83132962/127232.html
5. Lunardini CA. “Jordan, Barbara,” *Encyclopedia of African-American Culture and History* (1996; updated 2005), Encyclopedia.com. Supports that she was confined to a wheelchair by a degenerative disease in 1992 and that her obituaries explained much she had kept private, confirming multiple sclerosis. https://encyclopedia.com/history/encyclopedias-almanacs-transcripts-and-maps/jordan-barbara
6. Cooper-Dowda R. “Barbara Jordan: Hiding in Plain Sight While Working for ‘The Common Good’,” *Ragged Edge Magazine*, 2002. Supports that she walked with a cane before she left the House and said at the time that it was due to “a bum knee,” that she did not openly acknowledge her multiple sclerosis for years, and its account that her doctors made the disease public after a near-drowning it dates to 1994. https://www.raggededgemagazine.com/extra/bjordan.htm
7. Biography.com. “Barbara Jordan.” Supports that it was later revealed she had been diagnosed with multiple sclerosis around the time she announced she would not seek reelection, and the 1992 address from a wheelchair. https://www.biography.com/political-figures/barbara-jordan
8. Texas State Cemetery. “Barbara Charline Jordan.” Supports her birth and death dates and burial in the State Cemetery. https://cemetery.texas.gov/locate-a-plot/plotholder/barbara-charline-jordan
9. HISTMED Master Roster v3. Internal project source; not treated as independent corroboration.

## Clinical guidance

1. Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. American Academy of Neurology, *Neurology* 2018 (PMID 29686116). https://pubmed.ncbi.nlm.nih.gov/29686116/
2. Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol* 2018 (PMID 29275977). https://pubmed.ncbi.nlm.nih.gov/29275977/
3. Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. *Lancet Neurol* 2021 (PMID 34139157). https://pubmed.ncbi.nlm.nih.gov/34139157/
4. Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. American Academy of Neurology, *Neurology* 2019 (PMID 31462584). https://pubmed.ncbi.nlm.nih.gov/31462584/
5. OCREVUS (ocrelizumab) prescribing information, DailyMed: dosing (300 mg on day 1 and day 15, then 600 mg every 6 months), premedication, hepatitis B screening, quantitative immunoglobulins and liver tests before the first dose, live vaccines at least 4 weeks and non-live vaccines at least 2 weeks before, observation after each infusion, monitoring of immunoglobulins, and standard breast cancer screening. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9da42362-3bb5-4b83-b4bb-b59fd4e55f0d
6. National Institute for Health and Care Excellence. Multiple sclerosis in adults: management (NG220, 2022): baclofen first and gabapentin second for spasticity, and the fatigue, bladder, mobility and mood recommendations. https://www.nice.org.uk/guidance/ng220
7. Job Accommodation Network. Accommodation and Compliance: Multiple Sclerosis. https://askjan.org/disabilities/Multiple-Sclerosis.cfm; U.S. Department of Justice. Introduction to the Americans with Disabilities Act. https://www.ada.gov/topics/intro-to-ada/
8. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), osteoporosis monograph (secondary-cause laboratory work-up, 25-hydroxyvitamin D after repletion and then yearly, fall-risk screen) and depression monograph. https://patrickrutledge.github.io/topthirty/
9. Centers for Disease Control and Prevention. Adult Immunization Schedule by Age. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html
10. U.S. Preventive Services Task Force: A and B recommendations, depression (2023), breast cancer (2024), cervical cancer (2018), and colorectal cancer (2021). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
11. Medicare Preventive Services reference (Aether Forge, 2026). https://patrickrutledge.github.io/preventative_services/

## Editorial resolutions

- **Recent-death rule.** Jordan died in 1996, so the rule applies. The case uses only what was reported publicly in her life or in her obituaries, and reference works that summarize those reports: the Texas State Historical Association, the House history, the *Los Angeles Times* obituary, a Voice of America profile, an encyclopedia entry, Biography.com, the State Cemetery, and one disability-press article that reports what she said publicly at the time about her cane. No private medical record, family account or posthumous biography is used. No sick visit is added. Her death is recorded once (CLM-0010) as history, in one plain sentence; leukemia appears nowhere in the modern episode. No claim concerns mental health or substance use; the modern mood screens are synthetic and below the threshold for a safety assessment.
- **Private life.** Nothing about her private relationships is recorded. The near-drowning at her home is mentioned only inside the conflict claim (CLM-0008), without the people involved, and is not used in the modern episode. The modern social history records that household details were not recorded at her request, and names no one.
- **Conflicts.** (1) The year of diagnosis is not stated in the sources read. Biography.com says it was later revealed that she was diagnosed around the time she left Congress (CLM-0006, graded probable); a search summary attributed a 1973 diagnosis to an encyclopedia entry, but the entry fetched did not contain it, so 1973 is not used. (2) The date of disclosure differs: after she left Congress (Voice of America), after a near-drowning dated 1994 (*Ragged Edge*; the Texas State Historical Association dates the near-drowning to 1988 and does not link it to the disease), or in her obituaries (encyclopedia). CLM-0008 records all three as disputed. (3) Voice of America gives January 18, 1996, as her death date; the obituary, the House history, the Texas State Historical Association and the State Cemetery give January 17, which is preferred. (4) The cane and her “bum knee” explanation rest on one posthumous article (CLM-0005, graded probable).
- **Sources that could not be read.** The *New York Times* obituary could not be fetched and the Smithsonian page returned an error, so neither is cited.
- **Index age and dates.** The index visit on March 2, 2026 maps to March 2, 1980, when she was 44: about a year after she left the House for the LBJ School, and after walking problems that needed a cane in her last House years (the earliest documented mobility problem). The synthetic date of birth is February 21, 1982 (shift 46 years). The chronic-care visits on March 16, April 20, June 29 and October 26, 2026, the infusions on May 4 and May 18, and the preventive visit on August 17, 2026 (age 44, so a periodic adult preventive visit) map to the same days of 1980. Past medical history includes only the cane (1978) and the diagnosis around the time she left Congress (1979). Because the diagnosis predates the index visit, the intake problem is “multiple sclerosis, course not yet classified” (G35.D, resolved at the consultation), and the classified diagnosis is recorded at the consultation.
- **Synthetic clinical picture.** The course (primary progressive, active), the MRI findings, EDSS 6.0, the timed walk, the bladder and vitamin D findings, the past steroid courses, all laboratory values and serologies, the choice of ocrelizumab, and every medication are synthetic. Primary progressive disease was chosen because the public record describes a gradual loss of mobility (cane, then walker and wheelchair) with no reported attacks, so the episode adds no invented relapse; ocrelizumab is the therapy with evidence for that course, and the enhancing lesion makes her a likely responder at 44. Qualitative results (hepatitis B serology, varicella and measles immunity, tuberculosis blood test, HIV, hepatitis C, HPV, mammogram, MRI reports, post-void residual, bone density Z-scores) appear only in note text. Height (173 cm) and weights are synthetic.
- **Privacy and work.** Her documented wish to keep the disease private shapes the modern plan: the employer letter describes functional needs without the diagnosis, and she decides who receives each letter. Reproductive plans before ocrelizumab are recorded only as discussed privately. Disability is described as part of a full working life, without pity language.
- **Real people.** No real person has a role in the modern episode. The head of the LBJ School and a University of Texas official appear only as the obituary’s sources.
- **Preventive visit.** A periodic adult preventive visit at 44 (CPT 99396 with 99497 in plain text). Judgment calls: mammography every two years from 40 (USPSTF 2024), reinforced by the ocrelizumab label; primary HPV testing; colorectal screening not until 45; lipids and A1c; bone density at 44 because of reduced mobility and earlier steroid courses, reported as Z-scores, which apply before menopause; influenza and COVID-19 vaccines deferred to October, two weeks before the next infusion; chaperones offered for the breast and pelvic examinations. Advance care planning records only her general preferences and an unnamed agent.
- **Focused visits.** The four chronic-care follow-ups (two weeks with the consultation and MRI, five weeks, four months and eight months) are documented as focused visits on the AAN 2018 disease-modifying therapy guideline, the 2017 McDonald criteria, the 2021 MAGNIMS-CMSC-NAIMS MRI consensus, the AAN 2019 immunization guideline, the ocrelizumab label, NICE NG220 for symptom care, and the CMID osteoporosis and depression monographs. One deviation is recorded instead of an invented result: the physical therapy evaluation requested at intake had not happened by the five-week visit because of a waiting list; no harm resulted (no falls, gait unchanged), the clinic escalated to a second provider, and therapy began before the four-month visit. Synthetic findings introduced: a mild first-infusion reaction, CD19 depletion after the first doses, and a re-baseline MRI with no new or enlarging lesions. The next PHQ-9 is due after the episode ends.
- **Consultation.** The multiple sclerosis neurology referral and the consultation by Kenji Watanabe, MD (a fictional consultant), on the day of the two-week visit, are **S**. The consultant answers the seven referral questions in line with what the record shows afterwards: primary progressive, active disease under McDonald 2017; ocrelizumab, started nine weeks after intake after hepatitis B, pneumococcal, zoster and Tdap vaccination finished two weeks earlier; monitoring of counts, immunoglobulins and liver tests before each dose; a re-baseline MRI without gadolinium at five to six months; baclofen titrated to 10 mg three times a day; mirabegron with blood pressure checks; and a written relapse and pseudo-relapse plan, which she used correctly for heat-related symptoms in the summer.
